The information collection supports
agency guidance. Respondents to the collections are sponsors
holding Investigational New Drug Applications (INDs), New Drug
Applications (NDAs), and Biologics License Applicatons (BLAs). The
guidance makes recommendations to respondents with regarding what
pharmacogenomic data to submit to FDA during the drug development
process, the format of submissions, and how the data will be used
in regulatory decisionmaking.
US Code:
21 USC 301 et seq. Name of Law: Federal Food, Drug, and
Cosmetic Act
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.